Off-Label Prescribing in Personal Injury: What Insurers Should Know
When off-label medication use is evidence-based practice versus when it represents unjustified risk
Published 3 April 2026
The Off-Label Reality in Your Claims
Your claimant is taking a medication for an indication that's not listed on the product label. This isn't unusual. Off-label prescribing is common and often evidence-based. But sometimes it represents risk. You need to know the difference because your funding decisions depend on accurately assessing whether off-label use is supported by current evidence or represents unproven treatment at your expense.
Off-label prescribing in personal injury claims raises specific issues. Your claimant's injury creates unique demands: pain management without opioid dependence, functional improvement despite ongoing symptoms, recovery trajectory optimization. Sometimes prescribers use medications off-label because these needs are real and approved indications don't quite match. Other times, off-label use represents prescriber preference or experimentation at your cost. Your role is distinguishing between legitimate evidence-based off-label use and inappropriate medication experimentation.
What "Off-Label" Actually Means
Off-label prescribing means using a medication for an indication, dose, population, or duration that isn't listed in the approved product information. This happens in three main contexts in personal injury claims:
Indication Off-Label
Your medication is approved for one condition but prescribed for another. Amitriptyline is approved for depression but prescribed for neuropathic pain. Gabapentin is approved for neuropathic pain but prescribed for anxiety or insomnia. These are legitimate medical practices when evidence supports the off-label use. Your awareness should focus on whether the evidence supporting this off-label indication is robust.
Dose Off-Label
The dose prescribed is outside the approved range. Your claimant is on gabapentin 1800mg daily when approved indication suggests 900-1800mg. Are higher doses supported by evidence for the condition being treated? Or is dose escalation occurring without evidence supporting that higher doses provide additional benefit?
Duration Off-Label
The medication is prescribed longer than product information recommends. Benzodiazepines are approved for short-term anxiety (typically 2-4 weeks) but your claimant has been on them for two years. This off-label duration use is concerning because it suggests either failed deprescribing efforts or prescriber agreement that continued use is justified despite evidence recommending against long-term benzodiazepine use.
When Off-Label Use Is Evidence-Based
Many off-label prescribing practices are well-supported by clinical evidence and guidelines. Consider these established examples:
- Antidepressants (amitriptyline, venlafaxine, duloxetine) for chronic pain management are off-label by strict product labeling but are supported by clinical guidelines and multiple studies demonstrating efficacy
- Gabapentin for anxiety is off-label but has reasonable evidence base in anxiety management, particularly where anxiolytics are inappropriate
- Topiramate for migraine headache is off-label but is recommended in multiple guidelines for migraine prevention
- Low-dose naltrexone for pain is emerging evidence-based practice that involves off-label dosing
- Quetiapine at low dose for sleep disturbance is off-label but represents common evidence-based practice for insomnia when conventional sleep medications haven't worked
In these examples, off-label use is supported by clinical evidence, recommended in major guidelines, and represents accepted medical practice. Funding these medications involves standard clinical risk, not additional risk from off-label status.
Red Flags: When Off-Label Use Is Concerning
However, you should be alert to off-label uses that aren't supported by evidence or that represent prescriber preference rather than evidence-based practice:
Red Flag One: No Documented Rationale
Your prescriber prescribes a medication off-label without documenting why off-label use is necessary. Why is this medication being used for this indication? Have on-label alternatives been tried and failed? Is there specific clinical reasoning? If documentation is absent, off-label use might represent prescriber habit rather than evidence-based choice.
Red Flag Two: Limited or Emerging Evidence
Some off-label uses are based on emerging evidence from small studies or individual practitioner experience rather than established clinical evidence. Your claimant is receiving a medication for an indication where published evidence is limited and results are preliminary. This might be justified in cases where approved options have failed, but it represents additional clinical risk that you should acknowledge.
Red Flag Three: Dose Escalation Without Clear Rationale
Your claimant starts on a standard approved dose but doses escalate progressively beyond approved ranges without documented indication. Standard dose isn't working well, so your prescriber tries higher doses, but product information doesn't provide guidance and evidence for this escalation is unclear. You're now funding medication experimentation rather than evidence-based practice.
Red Flag Four: No Clear Stopping Point
Off-label medication is prescribed indefinitely without documented plan for reassessment or deprescribing. When will your prescriber assess whether off-label medication remains necessary? When might deprescribing be attempted? If none of these questions are addressed, off-label medication might persist beyond its clinical utility.
Off-Label Use in Specific Drug Classes
You should understand which off-label uses are well-established and which are more questionable:
| Drug Class | Common Off-Label Use | Evidence Status | Your Concern Level |
|---|---|---|---|
| Antidepressants | Chronic pain management | Well-established, guideline-supported | Low |
| Gabapentinoids | Anxiety, sleep, pain escalation | Moderate evidence for anxiety, emerging for higher doses | Moderate |
| Atypical antipsychotics | Sleep disturbance, anxiety | Limited evidence, more practitioner-driven | Moderate to high |
| Topical agents | Various pain syndromes | Good evidence for established uses, emerging for others | Low to moderate |
| Low-dose naltrexone | Chronic pain | Emerging evidence, limited but growing | Moderate |
Your Pharmacist's Role in Off-Label Assessment
Your pharmacist can assess off-label use quality. Ask your pharmacist to provide:
- What is the current evidence base for this off-label use? Are there clinical studies, guidelines, or expert recommendations supporting it?
- Is this off-label use supported by major therapeutic guidelines in Australia?
- Have appropriate on-label alternatives been tried first? Or has off-label medication been tried when on-label options might be equally effective?
- Is the prescribed dose supported by evidence, or is dose escalation occurring without clear evidence benefit?
- How long should off-label medication continue? When should effectiveness be reassessed?
- What are the specific safety considerations for this off-label use?
Documentation Requirements for Off-Label Funding
If you're funding off-label medication use, you should require specific documentation:
Written Rationale
Your prescriber should document specifically why off-label use is necessary. What on-label alternatives have been tried? Why did they fail? What is the specific clinical reasoning for off-label use? Don't accept vague justifications. Require specific documentation.
Evidence Reference
For emerging off-label uses (not established in guidelines), your prescriber should reference the clinical literature supporting the decision. What studies support this use? What clinical guidelines mention it? This creates accountability for prescribing decisions.
Monitoring Plan
How will your prescriber assess whether off-label medication is working? What specific measures will determine effectiveness? How long will off-label medication continue? When will effectiveness be reassessed? Document the plan, then follow it.
Exit Strategy
Off-label medications should not continue indefinitely without reassessment. Establish when effectiveness will be reassessed and what results would trigger deprescribing. This prevents off-label medications from becoming entrenched.
When to Challenge Off-Label Prescribing
You should challenge off-label use when:
- On-label alternatives exist and haven't been tried first
- Off-label indication lacks evidence and is based primarily on prescriber preference
- Off-label dose escalates beyond evidence-supported ranges without clear clinical rationale
- Off-label medication continues indefinitely without reassessment or documented stopping point
- Off-label use represents medication experimentation at your cost when evidence-based approved options haven't been optimized
- Prescriber cannot articulate clear clinical reasoning for off-label choice
When you challenge off-label prescribing, provide specific evidence-based alternative. Don't simply say "I won't fund off-label medication." Instead, say "I'll fund off-label medication when evidence supports it and on-label alternatives have been tried first. Current research suggests on-label option X might be more appropriate. Can we try that first?"
The Strategic Balance
Off-label prescribing is a legitimate medical practice that often provides genuine benefit. Your goal is not to eliminate off-label use but to ensure that when you fund off-label medication, it's supported by reasonable evidence and documented with clear clinical rationale. Some off-label uses represent innovative, evidence-based practice that improves your claimant's outcomes. Others represent medication experimentation that should have tried established options first.
Your pharmacist can help you navigate this complexity. Don't view off-label use as automatically problematic, but do require that off-label decisions be documented, evidence-based, and accountable. This approach supports your claimants' access to legitimate off-label treatments while protecting your funding from inappropriate medication experimentation.
Evidence-based assessment of off-label medication use.
IMM's pharmacists provide detailed analysis of off-label prescribing in your claims, ensuring funding decisions are based on current evidence and documented clinical reasoning.
Request a Medication Review
